Monthly Archives: January 2010

Fewer Public Biotechs in 2010 vs 2008

Back in January 2008, we were tracking 394 “active” public biotech companies. (By “active”, we mean companies that are filing with the SEC and not in bankruptcy or in a major restructuring due financial distress.) As of January 2010, we have 295 – a loss of ~25%. About 48% of the companies that are no longer “active” have been acquired and 52% have gone out of business, filed bankruptcy, or are no longer filing with Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

Weekly Blog Round Up

Biofuels are big in Iowa. So big in fact, that according to “Iowa State University will get $8 million of a $78 million U.S. Department of Energy grant to research and develop advanced biofuels.” “These Iowa State research projects are paid for by stimulus bucks … the same money that is funding the $44 million to the Donald Danforth Plant Science Center in St. Louis, Mo. (…..) and the $34 million (plus $8.4 million Read More >

Biofuels & Climate Change  |  1 Comment  |  Email This Post
Tags: , , , ,

BIO Asia partnering is heating up!

Less than a week to go until the 7th Annual BIO Asia International Partnering Conference and it is clear that we are on pace to beat the number of total partnering meetings done from last year. Check out the little snippet from Google analytics to the right.  This past Monday represented the highest day of activity within the system to date! In 2008, we had a total of 693 partnering meetings scheduled at the conference Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The Evolution of BIO Partnering

I joined BIO in the summer of 2008, just as the global biotechnology community headed towards sunny San Diego.  This was my first experience with the scale of partnering that occurs at that meeting.  Constantly trying to be on the forefront of innovation, the BIO BD team has put forth an increased effort into converting their partnering software form a utilitarian piece of software into something that is much more. The last 18 months have Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , ,

IP Professors: 12-Year Data Exclusivity a Win-Win for Patient Access & Biotech Innovation

David E. Adelman of the University of Texas School of Law and Christopher M. Holman of the University of Missouri – Kansas City School of Law recently published analysis on the “sideshow” of the data exclusivity debate in Washington.

Adelman and Holman use a cost-benefit analysis that incorporates the most important legal precedents and case law today in concluding that “policymakers should focus on mitigating the systematic barriers to entry that pose much greater and longer-term obstacles to lower-cost biotech drugs.” Specifically, the draft paper provides solid analysis of the need for 12-year data exclusivity, which the authors describe as a perfect balance between providing access to important medicines to patients, and creating the incentives needed for investors and companies to prepare (and survive) the regulatory approval process for follow-on biologics.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,